Publications by authors named "Lindy P Fox"
Article Synopsis
- Drug-induced hypersensitivity syndrome (DiHS), also known as DRESS, is a serious skin reaction that includes symptoms like fever and involvement of internal organs, commonly triggered by medications like anticonvulsants and antibiotics.
- The condition typically arises 2-6 weeks after drug exposure and is driven by a complex interaction between the drugs, viruses, and the immune system, particularly T-cells.
- This continuing medical education activity aims to inform healthcare professionals about the latest trends in DiHS/DRESS's epidemiology, underlying mechanisms, and clinical features for better prognosis and treatment.
Article Synopsis
- - Drug-induced hypersensitivity syndrome (DIHS) is a serious skin reaction that includes symptoms like rashes, fever, and problems with blood and organs, making it crucial to distinguish it from other similar conditions and diseases.
- - Although there are proposed diagnostic criteria for DIHS, there's no established consensus, so identifying the right cause can be complex and requires thorough evaluation.
- - The main treatment involves stopping the suspected drug immediately and using systemic corticosteroids, with ongoing research into alternatives; follow-up care is also essential to monitor for any long-term effects.
Article Synopsis
- * Data from 101 cases across 13 countries showed that skin lesions were often the first symptoms of infection, evolving from papules and vesicles to pustules and crusts/scabs as the infection progressed.
- * The research indicates notable differences from past outbreaks, including early skin lesions and a risk of scarring, while acknowledging potential biases in the registry data.
This retrospective study examines the association of lice infestation with iron-deficiency anemia and risk factors such as homelessness and physical disability.
View Article and Find Full Text PDFThis cross-sectional study examines the rates of group A skin and soft tissue infections among persons experiencing homelessness.
View Article and Find Full Text PDFCoronavirus disease 2019 (COVID-19), an emergent disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread throughout the globe since its discovery in December 2019. Although first appreciated to cause pneumonia, numerous organ systems are now known to be involved. The objective of this article is to review the broad spectrum of cutaneous manifestations reported in association with SARS-CoV-2 infection.
View Article and Find Full Text PDFArticle Synopsis
- The study examined skin reactions following COVID-19 vaccinations by reviewing reports from an international registry, focusing on those with available skin biopsy data.
- Out of 803 reported reactions, 58 cases had sufficient biopsy information, with spongiotic dermatitis being the most frequent histopathologic finding and led to the proposal of the acronym "V-REPP" for these reactions.
- The research identified 12 additional clinical patterns of skin reactions related to the vaccine, although it noted limitations in the data, indicating that not all cases could be analyzed for incidence rates.
Background: Cutaneous reactions after messenger RNA (mRNA)-based COVID-19 vaccines have been reported but are not well characterized.
Objective: To evaluate the morphology and timing of cutaneous reactions after mRNA COVID-19 vaccines.
Methods: A provider-facing registry-based study collected cases of cutaneous manifestations after COVID-19 vaccination.
Background: Coronavirus disease 2019 (COVID-19) has associated cutaneous manifestations.
Objective: To characterize the diversity of cutaneous manifestations of COVID-19 and facilitate understanding of the underlying pathophysiology.
Methods: Case series from an international registry from the American Academy of Dermatology and International League of Dermatological Societies.
Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in coronavirus disease 2019 (COVID-19) are scarce. This article reviews and offers guidance based on currently available safety data and the most recent COVID-19 outcome data in patients with immune-mediated dermatologic disease.
View Article and Find Full Text PDFBackground: Increasing evidence suggests pernio-like lesions are cutaneous manifestations of coronavirus infectious disease 2019 (COVID-19).
Objective: To describe clinical and pathologic findings of pernio-like lesions in patients with confirmed or suspected COVID-19.
Methods: An international dermatology registry was circulated to health care providers worldwide through the American Academy of Dermatology, International League of Dermatologic Societies, and other organizations.